Skip to content

Author

Joanna Kulpa

We have 4 of 10 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Sep 2026

Bromodomain inhibitors in autoimmune diseases.

Autoimmune diseases are very common worldwide. The immune system becomes dysregulated in a pro-inflammatory direction. Bromodomains play a crucial role in the regulation of many inflammatory pathways, including mitogen-activated protein kinase, nuclear factor kappa B, and interleukins. Bromodomain inhibitors could allo...

Marcin Szczepanik, Wojciech Pociej, Joanna Kulpa et al. · 0 citations
Open access Sep 2026

ADC – ANTIBODY-DRUG CONJUGATES IN ONCOLOGY

A thorough analysis of ADC possibilities in oncology focusing on treatment options, side effects of therapies for breast, bladder and lung cancers reveals ADC to be a promising treatment option as a innovative, more precise form of therapy.

Jędrzej Kowalski, Dominik Szymczak, Olaf Zołotar et al. · 0 citations
Review Open access Aug 2026

IRRITABLE BOWEL SYNDROME – NEW PERSPECTIVE

IBS is a complex medical condition, the usage of probiotics and other novel therapeutic agents may alleviate the severity of the disease and the understanding of the gut-brain axis as the basis of novel therapies shows promise in further implementation of more efficient treatment.

Joanna Kulpa, Kornelia Tyczka, Marcin Szczepanik et al. · 0 citations
Open access Aug 2026

CAR-T CELL THERAPY IN ONCOLOGY AND RHEUMATOLOGY

Background: CAR-T cell therapy is a highly personalized form of treatment. it involves modifying T cells extracted from the patients white blood cells during cell collection. Genetic modification of said T cells allows for the extraction of chimeric antigen receptor (CAR), which are later multiplied and infused into th...

Kornelia Tyczka, Marcin Szczepanik, M. Nowakowska et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.